Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences ( ($GILD) ) just unveiled an announcement. On August 10, 2025, Gilead Sciences announced the appointment of Erin Burkhart as ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...